Gout

Aspiration of a symptomatic joint or bursa for polarized-light microscopy is the preferred confirmatory test when the diagnosis is uncertain, the presentation is atypical, or infection is plausible. Detection of monosodium urate (MSU) crystals in synovial fluid or a tophus is sufficient for gout classification. A negative aspirate lowers, but does not eliminate, classification probability; the 2015 criteria assign negative points when trained microscopy does not identify MSU crystals. BMJ+1BMJ2015 Gout classification criteria: an American College of ...ScienceDirectSingle source dual-energy computed tomography in the ...

Exclude septic arthritis before using corticosteroids in a presumed crystal flare. This is especially consequential in chronic kidney disease, where NSAID avoidance and diabetes-related corticosteroid risk may narrow anti-inflammatory options, but neither circumstance justifies bypassing infection assessment. BMJBMJSafety and efficacy of colchicine in crystal-induced arthritis ...

If aspiration is unsuccessful or not feasible, use ultrasound for a double-contour sign or dual-energy CT (DECT) for urate deposition as supportive evidence. DECT has good diagnostic accuracy for MSU deposits but lower sensitivity in early disease; do not use a negative early DECT to exclude gout. BMJ+2BMJ2015 Gout classification criteria: an American College of ...BMJDual-energy CT for the diagnosis of gout: an accuracy and ...ScienceDirectAn updated systematic review and meta-analysis of randomised controlled trials on the effects of urate-lowering therapy initiation during a gout flare

Use colchicine, an NSAID, or glucocorticoids for a gout flare. The ACR guideline includes oral, intra-articular, and intramuscular glucocorticoids among first-line options, and comparative evidence indicates broadly similar flare control among oral colchicine, NSAIDs, and glucocorticoids, with different adverse-effect profiles. Wiley+1Wiley2020 American College of Rheumatology Guideline for the ...ScienceDirectAn updated systematic review and meta-analysis of randomised controlled trials on the effects of urate-lowering therapy initiation during a gout flare

For a patient without an NSAID contraindication, naproxen is a practical option. In the CONTACT trial, naproxen produced little difference in pain reduction versus low-dose colchicine but caused fewer adverse effects, less rescue analgesic use, and slightly lower costs; naproxen 500 mg twice daily has also demonstrated equivalence to prednisolone for gout flares. BMJBMJOpen-label randomised pragmatic trial (CONTACT ...

Use low-dose colchicine early in a flare when clinically appropriate. The AGREE low-dose regimen was 1.8 mg over 2 hours; ACR-cited practice may continue colchicine 0.6 mg once or twice daily until flare resolution. Avoid routine colchicine in severe CKD (G4–G5) under EULAR guidance, although observational evidence suggests cautiously reduced dosing with close monitoring may be possible in selected patients. BMJ+1BMJOpen-label randomised pragmatic trial (CONTACT ...BMJSafety and efficacy of colchicine in crystal-induced arthritis ...

Use systemic or local glucocorticoids when NSAIDs or colchicine are unsuitable, but first address infection risk. Short courses may have an acceptable risk-benefit profile in CKD, whereas diabetes and infection susceptibility are important tradeoffs. Nature+1NatureManagement of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities | Nature Reviews RheumatologyBMJSafety and efficacy of colchicine in crystal-induced arthritis ...

Discuss urate-lowering therapy (ULT) with patients who have recurrent attacks, tophi, urate arthropathy, renal damage, or symptomatic very high serum urate. Shared decision-making should explicitly incorporate expected benefits and limitations, comorbidities, concomitant drugs, and patient preference. BMJBMJLatest guidance on the management of gout

Use a treat-to-target strategy with serum urate below 6 mg/dL. Sustained urate reduction is intended to dissolve MSU crystals, suppress flares, and resolve tophi; allopurinol is the first-line ULT and should begin at a low dose with gradual escalation. Nature+2NatureGout | Nature Reviews Disease PrimersBMJLatest guidance on the management of goutWileyGout Flare Burden in the United States: A Multiyear Cross ...

Monitor serum urate and renal function repeatedly during dose titration and maintenance. A fixed allopurinol dose of 300 mg daily is often insufficient to achieve target serum urate, so a subtarget result should trigger adherence assessment and dose-adjustment planning rather than acceptance of persistent hyperuricemia. BMJBMJLatest guidance on the management of gout

Initiate anti-inflammatory prophylaxis when starting ULT because crystal deposit dissolution increases acute flare frequency during the early phase and can reduce adherence. High-quality evidence supports low-dose colchicine or low-dose NSAID prophylaxis in patients initiating ULT. Oxford Academic+1Oxford AcademicProphylaxis for acute gout flares after initiation of urate ...Annals of Internal MedicineManagement of Acute and Recurrent Gout: A Clinical ...

Use low-dose colchicine 0.5 mg once or twice daily or naproxen 250 mg orally twice daily as described first-line prophylaxis options, for up to 6 months. If these are contraindicated, not tolerated, or ineffective, low-dose prednisone or prednisolone may be considered; longer glucocorticoid exposure requires particular caution because cumulative toxicity can outweigh prophylactic benefit. Oxford Academic+1Oxford AcademicProphylaxis for acute gout flares after initiation of urate ...NatureManagement of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities | Nature Reviews Rheumatology

In CKD, individualize prophylaxis rather than automatically using standard regimens. EULAR recommends colchicine dose reduction for prophylaxis during the first 6 months of ULT, while long-term colchicine exposure has been associated with bone marrow suppression and neuromyotoxicity in the general population. BMJ+1BMJSafety and efficacy of colchicine in crystal-induced arthritis ...NatureManagement of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities | Nature Reviews Rheumatology

Consider pegloticase in patients with uncontrolled gout who have baseline serum urate at least 7 mg/dL and inability to maintain urate below 6 mg/dL on other ULT, intolerable adverse effects with current ULT, and/or clinically evident tophaceous deposits. In clinical trials, sustained urate below 6 mg/dL for more than 300 hours was observed with 8 mg and 12 mg doses in a dose-ranging study. dailymed nlm nihdailymed nlm nihKRYSTEXXA

For pegloticase therapy, assess clinical response using sustained serum urate control and tophus burden. In the labeled trial population, a month-6 responder maintained serum urate below 6 mg/dL for at least 80% of month 6; methotrexate coadministration produced a higher proportion of month-6 and month-12 responders than pegloticase alone. dailymed nlm nihdailymed nlm nihKRYSTEXXA

Plan infusion prophylaxis and flare prophylaxis before treatment. Trial participants received an oral antihistamine, intravenous corticosteroid, and acetaminophen for infusions, plus NSAID and/or colchicine flare prophylaxis beginning at least 1 week before therapy. dailymed nlm nihdailymed nlm nihKRYSTEXXA